Edition:
United Kingdom

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

248.20CHF
11:05am GMT
Change (% chg)

CHF-0.80 (-0.32%)
Prev Close
CHF249.00
Open
CHF249.00
Day's High
CHF249.00
Day's Low
CHF246.80
Volume
3,618
Avg. Vol
26,218
52-wk High
CHF255.00
52-wk Low
CHF209.40

Select another date:

Thu, Nov 1 2018

Photo

AbbVie, Roche combo treatment meets main goal of leukemia trial

(This Oct 31 story corrects paragraph one to say targeted therapy, not immunotherapy)

CORRECTED-AbbVie, Roche combo treatment meets main goal of leukemia trial

Oct 31 AbbVie Inc and Roche Holding AG said on Wednesday their targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker's cancer drug in a late-stage trial.

BRIEF-Roche Announces EU Approval Of Venclyxto Plus Mabthera

* ROCHE ANNOUNCES EU APPROVAL OF VENCLYXTO PLUS MABTHERA FOR PEOPLE WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

BRIEF-Roche Holding AG - Randomized Phase III CLL14 Study Met Its Primary Endpoint

* PHASE III DATA SHOWED THAT VENCLEXTA PLUS GAZYVA REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PEOPLE WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH CO-MORBIDITIES

BRIEF-Genentech Announces FDA Approval Of Xofluza For Influenza

* GENENTECH ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR INFLUENZA

BRIEF-Roche Announces FDA Approval Of Xofluza (Baloxavir Marboxil) For Influenza

* ROCHE ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR INFLUENZA Source text for Eikon: Further company coverage:

BRIEF-Roche Says Phase III Study On Alecensa Meets Primary Endpoint

* SAYS WILL TO ANNOUNCE RESULTS FROM THE PHASE III ALESIA STUDY, SHOWING THAT ALECENSA® (ALECTINIB) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED (INV) PROGRESSION-FREE SURVIVAL (PFS)

BRIEF-Roche CEO Says 'Confidence Rising' in Sales Growth in 2019, Beyond

* CEO SAYS HIS CONFIDENCE RISING QUARTER-BY-QUARTER THAT DRUGMAKER WILL CONTINUE SALES GROWTH IN 2019, BASED ON TRIAL RESULTS; "WE ARE SURE WE CAN OUTGROW THE IMPACT OF BIOSIMILARS"

BRIEF-Roche CEO Says Confident In Ability To Sustain Growth Beyond 2018

* SHARES SEEN RISING 1.9 PERCENT AFTER Q3 RESULTS - PREMARKET INDICATORS

BRIEF-Roche Launches Tumor Tissue Analysis Kits For Oncology Research

* ROCHE LAUNCHES NGS AVENIO TUMOR TISSUE ANALYSIS KITS FOR ONCOLOGY RESEARCH

Select another date: